Cyclosporin A treatment for membranoproliferative glomerulonephritis type II.

Abstract

A nephrotic patient with membranoproliferative glomerulonephritis type II (MPGN II) was treated with cyclosporin A (CSA) and alternate-day low-dose prednisolone. This patient developed the nephrotic syndrome twice. The second episode of the nephrotic syndrome was steroid resistant, and therefore this patient was treated with a CSA regimen. During treatments with alternate-day low-dose prednisolone and CSA, this patient recovered from the nephrotic syndrome. We conclude that CSA therapy may be effective for patients with the steroid-resistant nephrotic syndrome caused by MPGN II.

• Authors: Takahiro Kiyomasu, Minoru Shibata, Hideo Kurosu, Kazuhiro Shiraishi, Hisako Hashimoto, Tadashi Hayashidera, Yuichi Akiyama, Nobuaki Takeda
• Journal: Nephron (Nephron) Vol. 91 Issue 3 Pg. 509-11 (Jul 2002) ISSN: 1660-8151 [Print] Switzerland
• PMID: 12119488 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Complement C3
• Glucocorticoids
• Immunosuppressive Agents
• Cyclosporine
• Prednisolone

Topics

• Child
• Complement C3 (metabolism)
• Cyclosporine (therapeutic use)
• Glomerular Mesangium (cytology, pathology)
• Glomerulonephritis, Membranoproliferative (drug therapy)
• Glucocorticoids (therapeutic use)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Japan
• Male
• Prednisolone (therapeutic use)